AstraZeneca (AZN)
(Delayed Data from NSDQ)
$78.36 USD
+0.23 (0.29%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $78.35 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Astrazeneca (AZN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$85.34 | $97.00 | $74.00 | 9.23% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Astrazeneca comes to $85.34. The forecasts range from a low of $74.00 to a high of $97.00. The average price target represents an increase of 9.23% from the last closing price of $78.13.
Analyst Price Targets (8 )
Broker Rating
Astrazeneca currently has an average brokerage recommendation (ABR) of 1.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.57 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, 11 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 73.33% and 6.67% of all recommendations. A month ago, Strong Buy made up 73.33%, while Buy represented 6.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 10 | 9 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 0 | 0 |
ABR | 1.57 | 1.57 | 1.57 | 1.35 | 1.38 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/24/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
6/24/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
6/24/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
5/30/2024 | Goldman Sachs | Rajan Sharma | Not Available | Strong Buy |
5/29/2024 | UBS | Matthew Weston | Strong Sell | Strong Sell |
5/8/2024 | Not Identified | Not Identified | Hold | Hold |
4/26/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Steve M Scala | Strong Buy | Strong Buy |
3/15/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
2/20/2024 | Berenberg Bank | Luisa Hector | Not Available | Strong Buy |
12/18/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.57 |
ABR (Last week) | 1.57 |
# of Recs in ABR | 15 |
Average Target Price | $85.34 |
LT Growth Rate | 13.60% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 185 of 252 |
Current Quarter EPS Est: | 1.05 |